REGENXBIO presented positive initial data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular…
NicOx announced results from the phase 2b Mississippi trial which evaluated once-daily dosed NCX 4251 (fluticasone propionate ophthalmic suspension 0.1%) versus placebo in patients with…
New Jersey Institute of Technology (NJIT), a public research university in Newark New Jersey, secured a $3.7 million grant from the National Eye Institute of…
NicOx announced results from the phase 2b Mississippi trial which evaluated once-daily dosed NCX 4251 (fluticasone propionate ophthalmic suspension 0.1%) versus placebo in patients with…
AxeroVision announced positive results from a phase 2 trial of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
